Djavan Bob, Eckersberger Elisabeth, Finkelstein Julia, Sadri Helen, Taneja Samir S, Lepor Herbert
Department of Urology, New York University School of Medicine (NYU), New York University Hospital, 150 East 32nd Street, New York, NY 10016, USA.
Prim Care. 2010 Sep;37(3):441-59, vii. doi: 10.1016/j.pop.2010.05.001.
Prostate specific antigen (PSA) screening is an integral part of current screening for prostate cancer. Together with digital rectal examinations, it is recommended annually by the American Cancer Society. PSA screening has resulted in a significant stage migration in the past decades. Different forms of PSA, including free PSA, volume adjusted, complexed, intact, or pro-PSA, are being used in the screening process. Other aspects of the screening process include age at diagnosis, survival, overdiagnosis, and overtreatment. Recent studies have cast doubt on whether PSA screening positively affects mortality and how the quality of life of patients may be affected by screening. Future considerations include the need for more longitudinal studies as well as further study of the PSA components that may become more relevant in the future.
前列腺特异性抗原（PSA）筛查是当前前列腺癌筛查的一个重要组成部分。它与直肠指检一起，被美国癌症协会推荐每年进行一次。在过去几十年中，PSA筛查导致了显著的分期迁移。在筛查过程中使用了不同形式的PSA，包括游离PSA、体积校正PSA、复合PSA、完整PSA或前体PSA。筛查过程的其他方面包括诊断年龄、生存率、过度诊断和过度治疗。最近的研究对PSA筛查是否对死亡率有积极影响以及筛查可能如何影响患者的生活质量提出了质疑。未来需要考虑的是进行更多的纵向研究，以及进一步研究未来可能更相关的PSA成分。
